RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07080021, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Radiographic stage T≥3 or N≥1;

    Inclusion criterion 5

  3. Performance Status :ECOG (Eastern Cooperative Oncology Group) performance status ≤1 .

    Inclusion criterion 15

  4. Pregnancy or Lactation Female subjects who are pregnant or breastfeeding.

    Exclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07080021, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subjects meeting ALL of the following criteria will be enrolled:
  • Age and Gender :Aged 18-75 years, regardless of gender.
  • Diagnosis and Disease Stage :

Pathologically confirmed pancreatic cancer, meeting NCCN guideline criteria for:

A. High-risk resectable (meeting ≥1 criterion):

  • Luminal stenosis of the portal vein or superior mesenteric vein on imaging;
  • Radiographic stage T≥3 or N≥1;
  • Serum CA19-9 ≥1000 U/mL (after resolution of jaundice);
  • Confirmed regional lymph node metastasis;
  • Significant weight loss (>10% baseline) or severe pain requiring opioids.

B. Borderline resectable :

  • Tumor involving the common hepatic artery without celiac axis contact;
  • Tumor contact with SMA ≤180°.

C. Locally advanced (unresectable):

  • Tumor encasement (>180°) of the SMA, celiac axis, or common hepatic artery;
  • Unreconstructable involvement of SMV/portal vein;
  • No distant metastasis.
  • Treatment Suitability :Deemed suitable for neoadjuvant therapy after multidisciplinary team (MDT) discussion .
  • Performance Status :ECOG (Eastern Cooperative Oncology Group) performance status ≤1 .
  • Life Expectancy :Estimated survival ≥6 months.
  • Organ Function :No severe cardiac, hepatic, or renal dysfunction, including:

ALT/AST ≤3×ULN (upper limit of normal); Serum creatinine ≤1.5×ULN .

  • Informed Consent :Signed written informed consent voluntarily provided.

Exclusion Criteria:

  • Subjects meeting ANY of the following criteria will be excluded:
  • Distant Metastasis Radiographically confirmed distant metastatic lesions.
  • Prior Anti-Tumor Therapy History of any prior anti-tumor treatment, including:

Systemic chemotherapy Radiotherapy Interventional therapy Immunotherapy Targeted therapy Anti-tumor traditional Chinese medicine therapy.

  • Concurrent Malignancy Diagnosis of other active malignancies.
  • Pregnancy or Lactation Female subjects who are pregnant or breastfeeding.
  • Drug Allergy Hypersensitivity to any agents in the guideline-recommended first-line neoadjuvant regimen .
  • Transplantation History Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation .
  • Immunodeficiency Disorders Congenital or acquired immunodeficiency, including:

Human Immunodeficiency Virus (HIV) infection;

Active Hepatitis B :

HBsAg-positive andHBV-DNA ≥10,000 copies/mL (≥2,000 IU/mL) at screening;

Active Hepatitis C :

HCV-Ab-positive andHCV-RNA positive at screening; Co-infection with HBV and HC

Quoted from ClinicalTrials.gov, NCT07080021, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07080021, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07080021